MRNA April 2nd Options Begin Trading

Moderna (MRNA) is the subject of two option strategies: a sell-to-open $40 put bid $3.15 (underlying $40.36) which sets an effective purchase basis of $36.85 and carries a 58% probability of expiring worthless, yielding 7.88% (58.71% annualized) on cash at risk. A covered-call using the $42 strike bid $2.74 would provide a 10.85% total return if called at the April 2 expiration, with a 48% chance of expiring worthless and a 6.79% (50.61% annualized) premium boost; implied volatilities are high (put 92%, call 87%) versus trailing 12-month volatility of 66%.

Analysis

Market structure: The immediate winners are option premium sellers and liquidity providers capturing rich IV (puts IV 92%, calls 87% vs realized 66% — ~40% premium). Buyers of the underlying who want entry can lower effective basis to $36.85 by selling the Apr-2 $40 put; holders selling Apr-2 $42 calls can lock ~10.85% to-expiry upside. Market-level implication: high option skew concentrates risk in MRNA-specific catalysts (data/FDA) rather than broad biotech beta, increasing idiosyncratic flows and temporary mispricing.

Risk assessment: Tail risks are binary trial/regulatory outcomes that can move the stock >30% in days — IV already prices this but may spike beyond 150% on surprise news. Near-term (days–weeks) volatility is dominated by option expiries (Apr 2); short-term hedges should be 1–4 week calibrated. Hidden dependencies include dealer gamma hedging that can amplify intraday moves and forced buying/selling; monitor open interest and dealer delta exposure within 48 hours of major announcements.

Trade implications: Preferred tactical trades are premium-selling structures sized small: cash-secured $40 put (collect ~$3.15) or covered $42 call if long at $40.36; convert to credit spreads to cap assignment risk. For volatility-focused books, sell short-dated premium and hedge with cheap longer-dated puts (calendar/iron-condor) — target capture of the ~40% IV gap, but keep stop-loss rules for IV spikes >130% or >15% price gaps.

Contrarian angles: Consensus underestimates path-dependency — if MRNA posts benign news, IV collapse could cost long-vol positions and reward short-vol sellers; conversely a surprise adverse event will wipe out put sellers. Historical parallels (biotech binary events) show ±30–50% moves; thus naked sellers are being paid for risk that occurs infrequently but is severe — price accordingly and size conservatively.

Key Decisions for Investors

• If willing to own MRNA, establish a cash‑secured sell-to-open Apr‑2 2026 $40 put (~$3.15) sized to 1–3% of portfolio; target effective basis $36.85. Convert immediately to a bull put spread (buy Apr‑2 $37.50 or $35 put) if you want downside protection — cap max loss at strike width.
• If already long MRNA, sell-to-open Apr‑2 2026 $42 covered calls (~$2.74) on up to 3% position to lock ~10.85% to-expiry return; set rule to buy-to-close at $42 or if stock gaps >+8% intraday to avoid assignment arbitrage.
• Implement a small short-dated vol strategy: sell Apr short-dated strangles/iron-condors sized <0.5% equity, hedge with long OTM puts (~10% delta) and cut positions if IV >130% or stock moves >15% in 1 day. Target capture of the ~40% IV vs realized edge.
• Avoid naked large put positions >5% exposure across biotech names before confirming absence of near-term binary catalysts; monitor SEC/clinical calendars and close short‑vol 5–7 days ahead of known data/FDA events.